Pulse Biosciences (NASDAQ:PLSE) Trading 13.6% Higher – What’s Next?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) traded up 13.6% on Thursday . The stock traded as high as $27.58 and last traded at $28.39. 82,893 shares traded hands during trading, a decline of 74% from the average session volume of 324,168 shares. The stock had previously closed at $24.99.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Pulse Biosciences in a research note on Thursday. They set a “buy” rating and a $32.00 target price for the company. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Tuesday, April 21st. Finally, Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.67.

Pulse Biosciences Price Performance

The company’s 50 day moving average price is $22.70 and its 200 day moving average price is $18.78. The firm has a market cap of $1.75 billion, a PE ratio of -23.03 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.25 million. Sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Robert W. Duggan purchased 660,233 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the purchase, the director directly owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Paul A. Laviolette purchased 15,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $19.69 per share, with a total value of $295,350.00. Following the purchase, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at $295,350. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 74.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after acquiring an additional 1,300 shares during the last quarter. Westside Investment Management Inc. lifted its stake in Pulse Biosciences by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock worth $911,000 after acquiring an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.